New In Silico Software Release
22/11/2021 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211122:nRSV0198Ta&default-theme=true
RNS Number : 0198T Instem plc 22 November 2021
Instem plc
("Instem" or the "Company")
New In Silico Software Release
Enhanced Informatics Software Boosting Client Offering and Revenue Streams
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces the release of the latest edition of its Leadscope
Model Applier computational toxicology software solution. This release
includes a comprehensive package of new and updated models to meet the growing
market demand for in silico solutions and is expected to create the following
opportunities for Instem:
· New routes to market
· Increased revenue streams
· Strengthened in silico offering
· Increased regulatory-backed solutions
The core software capabilities have been enhanced significantly, enabling
clients to deploy a unique, highly-differentiated solution developed with
considerable regulatory and industry collaboration. The new software brings
compelling benefits; reducing the time to bring products to market, the risk
of costly later stage R&D failure and use of animal experimentation.
The software includes four new chargeable models. These include a
first-to-market Bioactivation Profiler, which was developed in conjunction
with regulators and industry. Additionally, the new Abuse Liability Profiler
is believed to be the first commercial in silico tool in the market, further
differentiating Instem from its competitors and broadening routes to market.
Renowned for its advanced informatics and prediction technology, together with
comprehensive database solutions, Instem's in silico
(https://www.instem.com/solutions/insilico/computational-toxicology.php)
solutions
(https://www.instem.com/solutions/insilico/computational-toxicology.php)
enable organizations around the world to effectively unlock valuable
knowledge contained in both public and proprietary sources of research data.
Clients can also access well over 500,000 toxicology studies for more than
200,000 chemicals, enabling fast, accurate, defendable and regulatory-accepted
predictions.
Dr. Glenn Myatt, VP Informatics of Instem plc, said: "The 2021 software
release supports the continued global demand for reliable alternatives to
traditional testing methods. Industry and regulators alike are increasingly
recognizing the huge benefits of computational toxicology approaches and we
are seeing strong and sustained growth in the acceptance and adoption of in
silico methods.
This latest software release enables existing and prospective clients to
accelerate their drug discovery and development processes by ensuring fast,
accurate, defendable and regulatory accepted predictions for an increasing
range of applications."
Phil Reason, CEO of Instem plc, said: "We are delighted to have released this
new 2021 software. This update further consolidates Instem's position as the
leading provider of alternative testing methods, delivering powerful new in
silico models and first-to-market capabilities.
Since acquiring Leadscope in November 2019, we have seen compound annual
growth rates for their software subscriptions of c.17% and pay-per-use growth
of 21% per annum. These new predictive models provide further opportunity
for revenue expansion."
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all the
largest 25 pharmaceutical companies, enabling clients to bring life enhancing
products to market faster. Instem's portfolio of software solutions increases
client productivity by automating study-related processes while offering the
unique ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform at some stage of their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
About Leadscope
Founded in 1997, Leadscope is based in Columbus, Ohio, USA and is a leading
provider of in silico safety assessment software used to enhance and
accelerate life sciences research and development. Developed, in part, through
several Research Collaboration Agreements ("RCAs") with the US Food & Drug
Administration ("FDA"), its solutions use a database of over 500,000 toxicity
studies for over 200,000 chemicals covering all major potential safety-related
risks.
Provided on a subscription or pay-per-use basis, Leadscope's software employs
sophisticated artificial intelligence and machine-learning algorithms to
predict potential safety outcomes and to enable scientists to perform expert
reviews. Deployed as Software-as-a-Service, or on client premises, Leadscope's
software allows clients to extract knowledge from both public data and their
own proprietary sources. Commencing in early 2021, access to the Leadscope
technology was additionally made available through a new Predict™ service.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRABLBATMTJBBFB